EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access

A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study)

Ian M McGowan iD, Sylvain Chawki, Craig W Hendrix, Peter A Anton, Mark A Marzinke, Rhonda M Brand, Jarret C Engstrom, Lisa C Rohan, Kaleab Z Abebe, Nicola Richardson-Harman, Aaron Siegel, Alex Reinhart und 8 weitere

AIDS Research and Human Retroviruses · 2022-04 · 38 (4) · 269-278

DOI: 10.1089/aid.2021.0096 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift AIDS Research and Human Retroviruses, online erschienen am 06.04.2022. Verfasst von Ian M McGowan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Orion Biotechnology, Ottawa, Canada. Hauptthemen laut MEDLINE: Anti-HIV Agents, Anti-Infective Agents, HIV Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Combination HIV Antiretroviral Rectal Microbicide-3 (CHARM-03) study was a randomized, open-label, crossover Phase 1 safety and pharmacokinetic (PK) study of oral maraviroc (MVC) and MVC 1% gel. At a single site, healthy HIV-uninfected men and women were enrolled and randomized to an open label crossover sequence of eight consecutive daily exposures to MVC 300 mg dosed orally, MCV 1% gel dosed rectally, and MVC 1% gel dosed vaginally. Male participants received oral and rectal dosing and female participants received oral, rectal, and vaginal dosing. Assessments were undertaken at baseline and following each 8-day period and included collection of plasma, rectal/cervical tissue (CT), and rectal/endocervical/vaginal fluids. Eleven men and nine women were enrolled. Two participants withdrew from the study before receiving study product. There were 25 adverse events, of which 24 were Grade 1 (G1) and one was G2 (unrelated). After eight doses, MVC was quantifiable in all samples following oral, rectal, or vaginal product administration. The highest drug concentrations in plasma, rectal tissue (RT), and CT were associated with oral, rectal, and vaginal drug delivery, respectively. There were significant reductions in tissue drug concentrations when rectal and cervical biopsies were incubated in media before tissue processing for PK ( p < .0001). Only oral MVC was associated with limited protection in the rectal explant HIV challenge model ( p < .05). There were no immunological changes in RT, and all products were acceptable to participants. In conclusion, all products were found to be safe and acceptable and did not induce local inflammation. The lack of ex vivo efficacy demonstrated in study samples may be due to rapid disassociation of MVC from the explant tissue. ClinicalTrials.gov Identifier: NCT02346084.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsAnti-Infective AgentsHIV InfectionsAnti-Retroviral AgentsCyclohexanesFemaleHumansMaleMaraviroc

Stichwörter der Autor:innen

HIVmaravirocmicrobicidepreventionrectal

Substanzen

Anti-HIV AgentsAnti-Infective AgentsAnti-Retroviral AgentsCyclohexanesMaraviroc

Autor:innen und Institutionen

  • Orion Biotechnology, Ottawa, Canada.
  • Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA.
  • INSERM, Paris, France.
  • Department of Virology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, France.
  • Division of Clinical Pharmacology, Johns Hopkins University, Baltimore, Maryland, USA.

ORCID-Profile: Ian M McGowan, Sharon L Achilles, Ross D Cranston

Förderung

  • NIAID NIH HHS

Zitieren

APA

McGowan, I. M., Chawki, S., Hendrix, C. W., Anton, P. A., Marzinke, M. A., Brand, R. M., Engstrom, J. C., Rohan, L. C., Abebe, K. Z., Richardson-Harman, N., Siegel, A., Reinhart, A., Steytler, J., Stall, R., Spiegel, H., Chen, B., Achilles, S. L., Jacobson, C. E., Khanukova, E., & Cranston, R. D. (2022). A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study). AIDS Research and Human Retroviruses, 38(4), 269-278. https://doi.org/10.1089/aid.2021.0096

Vancouver

McGowan IM, Chawki S, Hendrix CW, Anton PA, Marzinke MA, Brand RM, et al. A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study). AIDS Research and Human Retroviruses. 2022;38(4):269-278. doi:10.1089/aid.2021.0096

BibTeX
@article{McGowan2022,
  author = {McGowan, Ian M and Chawki, Sylvain and Hendrix, Craig W and Anton, Peter A and Marzinke, Mark A and Brand, Rhonda M and Engstrom, Jarret C and Rohan, Lisa C and Abebe, Kaleab Z and Richardson-Harman, Nicola and Siegel, Aaron and Reinhart, Alex and Steytler, John and Stall, Ronald and Spiegel, Hans and Chen, Beatrice and Achilles, Sharon L and Jacobson, Cindy E and Khanukova, Elena and Cranston, Ross D},
  title = {A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study)},
  journal = {AIDS Research and Human Retroviruses},
  year = {2022},
  volume = {38},
  number = {4},
  pages = {269--278},
  doi = {10.1089/aid.2021.0096}
}
Kostenlos starten →